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Chinese hamster ovary (CHO) cells are widely used industrially for the production of biotherapeutic proteins. In 
order to generate recombinant CHO cell lines expressing the target biotherapeutic gene(s) of interest, metabolic 
markers are used to select for those cells that have stably incorporated the gene(s) of interest. Such selection 
systems work very efficiently but do not directly select cells based upon secreted biotherapeutic recombinant 
protein productivity characteristics. When such biotherapeutic proteins are synthesised in eukaryotic cells, 
typically the polypeptide is co-translationally fed into the endoplasmic reticulum where it is folded, and if 
required, assembled with other polypeptides/domains, as in the case of antibodies. An overload of the capacity 
of the ER to fold and assemble recombinant proteins can result in upregulation of ER-associated degradation 
(ERAD) where unfolded or incorrectly folded or assembled material is retro-translocated out of the ER to the 
proteasome for degradation and recycling of amino acids. We have therefore investigated whether the 
susceptibility of cells to proteasome inhibitors during cell line construction when a recombinant load is placed 
upon the cell can be used to select for cells with a greater capacity for producing recombinant biotherapeutic 
proteins whilst maintaining or enhancing the quality of the material secreted. A number of proteasome inhibitors 
were therefore investigated, epoxomicin, MG-132 and bortezomib, at different concentrations to identify 
concentrations that would provide selection but not result in complete cell death. A range of concentrations was 
then added to CHO cells, along with MSX, during cell pool construction using Lonza’s CHOK1SV GS-KO™ 
proprietary host cell line to investigate whether this resulted in the generation of cell pools with enhanced 
productivity characteristics as compared to selection using MSX alone. Using this approach, and a number of 
different recombinant biotherapeutic molecules, we have found that CHO pools giving enhanced product 
concentrations can be generated (see Figure 1 for example) and validated this in ambr15 miniature bioreactor 
experiments. We have thus shown that stable transfectants derived from pools that had been cultured with 
proteasome inhibitors were more productive than pools generated without proteasome inhibitors. Further, stable 
transfectants generated using proteasome inhibitors retained their higher productivity characteristics even when 
the proteasome inhibitors were no longer added at subculture, meaning that proteasome inhibitors are only 

































Figure 1 – Lonza CHOK1SV GS-KO™ cells were 
transfected with a DNA vector encoding the 
expression of glutamine synthetase (GS) and 
a monoclonal antibody, using Lonza’s 4D-
Nucleofector device. Stable transfectant 
minipools in 96-well plates were selected 
using glutamine-free culture medium and 
methionine sulphoximine (MSX), with or 
without the proteasome inhibitors epoxomicin, 
MG-132 or bortezomib. After a fed-batch 
overgrow of minipools in 96-well deep-well 
plates, product concentration was measured 
using FortéBio’s Octet. The top 8 
concentrations obtained from each plate are 
shown here. 
